EIF2A and lip and oral cavity carcinoma: Here, we report that dasatinib has anti‐growth, anti‐angiogenic and pro‐apoptotic effects on both YD‐38 (non‐tumorigenic) and HSC‐3 (tumorigenic) human oral cancer cells, and these effects are mediated through control of the expression and phosphorylation of multiple targets including Src, EGFR, STAT‐3, STAT‐5, PKB, ERK‐1/2, S6, eIF‐2α, GRP78, caspase‐9/3, Mcl‐1 and HIF‐1α.